BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Naloxone (Narcan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Naloxone (Narcan)\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07022717-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Naloxone (Narcan): Phase na readout est. (NCT07022717)
DESCRIPTION:Naloxone (Narcan)\, phase na.\nStudy: A Universal Primary Care 
 Based Intervention to Reduce Youth Overdose Risk\nEstimated primary comple
 tion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 naloxone-narcan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07022717
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05490134-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Naloxone (Narcan): Phase 1 readout est. (NCT05490134)
DESCRIPTION:Naloxone (Narcan)\, phase 1.\nStudy: RM1 Project 1 - tAN Naloxo
 ne\nEstimated primary completion: 1 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/naloxone-narcan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05490134
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05011266-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Naloxone (Narcan): Phase 2/3 readout est. (NCT05011266)
DESCRIPTION:Naloxone (Narcan)\, phase 2/3.\nStudy: Efficacy of Buprenorphin
 e and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disor
 der\nEstimated primary completion: 1 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/naloxone-narcan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05011266
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05027919-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Naloxone (Narcan): Phase 2 readout est. (NCT05027919)
DESCRIPTION:Naloxone (Narcan)\, phase 2.\nStudy: Assessing a Clinically-mea
 ningful Opioid Withdrawal Phenotype\nEstimated primary completion: 30 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/naloxone-na
 rcan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05027919
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05450718-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:Naloxone (Narcan): Phase 4 readout est. (NCT05450718)
DESCRIPTION:Naloxone (Narcan)\, phase 4.\nStudy: Low-dose Buprenorphine Ini
 tiation for Opioid Use Disorder\nEstimated primary completion: 17 March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/naloxone-narcan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05450
 718
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05886712-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Naloxone (Narcan): Phase na readout est. (NCT05886712)
DESCRIPTION:Naloxone (Narcan)\, phase na\, Opioid Overdose.\nStudy: Improvi
 ng Access to Naloxone to Prevent Opioid Overdose Deaths (SAIA-Naloxone)\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/naloxone-narcan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05886712
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079241-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Naloxone (Narcan): Phase na readout est. (NCT07079241)
DESCRIPTION:Naloxone (Narcan)\, phase na\, Opioid Overdose.\nStudy: A Model
  to Save Lives Through a Volunteer First Responder Service Providing Antid
 ote Treatment in Opioid Overdose\nEstimated primary completion: 31 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/naloxone-narcan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 79241
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05528848-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Naloxone (Narcan): Phase 1 readout est. (NCT05528848)
DESCRIPTION:Naloxone (Narcan)\, phase 1.\nStudy: Multi-System Analysis of O
 pioid Receptor Binding\nEstimated primary completion: September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/naloxone-narcan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05528848
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04893525-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Naloxone (Narcan): Phase 2/3 readout est. (NCT04893525)
DESCRIPTION:Naloxone (Narcan)\, phase 2/3.\nStudy: Evaluating Buprenorphine
 /Naloxone Microdosing vs. Standard Dosing in Emergency Departments\nEstima
 ted primary completion: December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/naloxone-narcan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04893525
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839182-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Naloxone (Narcan): Phase na readout est. (NCT07839182)
DESCRIPTION:Naloxone (Narcan)\, phase na.\nStudy: Measurement-Based Care to
  Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics\
 nEstimated primary completion: 1 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/naloxone-narcan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07839182
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251609-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Naloxone (Narcan): Phase 2 readout est. (NCT06251609)
DESCRIPTION:Naloxone (Narcan)\, phase 2\, Opioid Overdose.\nStudy: Naloxone
  for Opioid Associated Out of Hospital Cardiac Arrest\nEstimated primary c
 ompletion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/naloxone-narcan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06251609
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06089707-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Naloxone (Narcan): Phase 3 readout est. (NCT06089707)
DESCRIPTION:Naloxone (Narcan)\, phase 3.\nStudy: Behavioral Pharmacological
  Examination of a Novel Buprenorphine Induction Method Among Individuals W
 ho Use Fentanyl\nEstimated primary completion: 1 January 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/naloxone-narcan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06089707
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04811014-8925@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Naloxone (Narcan): Phase 4 readout est. (NCT04811014)
DESCRIPTION:Naloxone (Narcan)\, phase 4\, Opioid Overdose.\nStudy: Young Ho
 uston Emergency Opioid Engagement System\nEstimated primary completion: 31
  August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/naloxon
 e-narcan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04811014
URL:https://assetmemo.bio/drug/naloxone-narcan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
